Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Thyroid cancer patients may spend less time in discomfort with simple phone calls

NCT ID NCT01298323

Symptom relief Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 3 trial tested whether a patient outreach program—regular phone calls every two weeks—could help people with advanced medullary thyroid cancer spend less time experiencing moderate-to-severe side effects from the drug vandetanib. The study enrolled 205 adults and compared those who received the outreach calls to those who did not. The goal was to see if early detection and management of side effects could improve the treatment experience.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vandetanib
What this could lead to
If successful, this outreach program could help patients on vandetanib spend less time dealing with bothersome side effects, improving their daily quality of life.
What could go wrong
This study focuses on managing side effects, not on curing cancer. The outreach program may not significantly reduce side effects, and results may not apply to other cancer types or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

205 people

The number who actually took part.

Started

Feb 2011

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provision of informed consent prior to any study specific procedures * Female or male aged 18 years and over * Previously confirmed histological diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic MTC. Documentation must be provided in patient's medical chart * WHO or ECOG Performance status 0-2 * Negative pregnancy test (urine or serum) for female patients of childbearing potential Exclusion Criteria: * Unstable brain metastases or spinal cord compression that require treatment, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days * Major surgery within 4 weeks before randomization * The last dose of prior chemotherapy received less than 3 weeks prior to randomization * Radiation therapy not completed prior to the first dose of vandetanib * Significant cardiac event, superior vena cava syndrome, NYHA classification of heart disease ≥2, within 12 weeks before randomization, or presence of cardiac disease that in the opinion of the Investigator increases risk of ventricular arrhythmia * Creatinine clearance \<30 ml/min (calculated by Cockcroft-Gault formula),Patients with moderate renal impairment, defined as creatinine clearance ≥30 to \<50 ml/min, must start vandetanib at a reduced dose of 200 mg

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Locally advanced or metastatic medullary thyroid cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary familial medullary thyroid carcinoma medullary thyroid gland carcinoma Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced or metastatic medullary thyroid cancer Medullary thyroid cancer

Contacts and locations

Locations

  • Faculdade de Medicina de Ribeirao Preto - USP Site Number : 702

    Ribeirão Preto, São Paulo, 14048-900, Brazil

  • Hospital De Clinicas De Porto Alegre Site Number : 701

    Porto Alegre, Rio Grande do Sul, 90035-003, Brazil

  • Investigational Site Number 1001

    London, N6A 4L6, Canada

  • Investigational Site Number 1002

    Sherbrooke, J1H 5N4, Canada

  • Investigational Site Number 1003

    Toronto, M5G2M9, Canada

  • Investigational Site Number 1301

    Beijing, 100021, China

  • Investigational Site Number 1302

    Shanghai, China

  • Investigational Site Number 1901

    Prague, 15006, Czechia

  • Investigational Site Number 2001

    Odense C, 5000, Denmark

  • Investigational Site Number 2201

    Helsinki, FI-00029, Finland

  • Investigational Site Number 2601

    Würzburg, 97080, Germany

  • Investigational Site Number 2602

    Essen, 45122, Germany

  • Investigational Site Number 2603

    Halle, 06120, Germany

  • Investigational Site Number 2801

    Sutton, SM25PT, United Kingdom

  • Investigational Site Number 2802

    Glasgow, G120YN, United Kingdom

  • Investigational Site Number 3001

    Athens, 11528, Greece

  • Investigational Site Number 301

    St Leonards, 2065, Australia

  • Investigational Site Number 3501

    Mumbai, 400012, India

  • Investigational Site Number 3502

    Vellore, 632004, India

  • Investigational Site Number 4001

    Jerusalem, 91120, Israel

  • Investigational Site Number 401

    Vienna, 1901, Austria

  • Investigational Site Number 4101

    Pisa, 56124, Italy

  • Investigational Site Number 4102

    Roma, 00161, Italy

  • Investigational Site Number 4104

    Naples, Italy

  • Investigational Site Number 501

    Brussels, 1000, Belgium

  • Investigational Site Number 5702

    Poznan, 60-355, Poland

  • Investigational Site Number 5703

    Warsaw, 02-781, Poland

  • Investigational Site Number 6001

    Seoul, South Korea

  • Investigational Site Number 6201

    Moscow, 115478, Russia

  • Investigational Site Number 6202

    Obninsk, 249036, Russia

  • Investigational Site Number 6203

    Saint Petersburg, 197022, Russia

  • Investigational Site Number 6204

    Moscow, 125284, Russia

  • Investigational Site Number 701

    Porto Alegre, 90035-003, Brazil

  • Investigational Site Number 702

    Ribeirão Preto, 14048-900, Brazil

  • Investigational Site Number 7201

    Uppsala, 75185, Sweden

  • Investigational Site Number 901

    Sofia, 1527, Bulgaria

  • Investigational Site Number : 1001

    London, Ontario, N6A 4L6, Canada

  • Investigational Site Number : 1002

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Investigational Site Number : 1003

    Toronto, Ontario, M5G2M9, Canada

  • Investigational Site Number : 1301

    Beijing, 100021, China

  • Investigational Site Number : 1302

    Shanghai, China

  • Investigational Site Number : 1901

    Prague, 15006, Czechia

  • Investigational Site Number : 2001

    Odense C, 5000, Denmark

  • Investigational Site Number : 2201

    Helsinki, FI-00029, Finland

  • Investigational Site Number : 2601

    Würzburg, 97080, Germany

  • Investigational Site Number : 2602

    Essen, 45122, Germany

  • Investigational Site Number : 2603

    Halle, 06120, Germany

  • Investigational Site Number : 2801

    Sutton, Surrey, SM25PT, United Kingdom

  • Investigational Site Number : 2802

    Glasgow, G120YN, United Kingdom

  • Investigational Site Number : 3001

    Athens, 11528, Greece

  • Investigational Site Number : 301

    St Leonards, New South Wales, 2065, Australia

  • Investigational Site Number : 3501

    Mumbai, 400012, India

  • Investigational Site Number : 3502

    Vellore, 632004, India

  • Investigational Site Number : 4001

    Jerusalem, 91120, Israel

  • Investigational Site Number : 401

    Vienna, 1901, Austria

  • Investigational Site Number : 4101

    Pisa, 56124, Italy

  • Investigational Site Number : 4102

    Roma, 00161, Italy

  • Investigational Site Number : 4104

    Naples, Italy

  • Investigational Site Number : 501

    Anderlecht, 1070, Belgium

  • Investigational Site Number : 5702

    Poznan, Greater Poland Voivodeship, 60-355, Poland

  • Investigational Site Number : 5703

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Investigational Site Number : 6001

    Seoul, 03080, South Korea

  • Investigational Site Number : 6201

    Moscow, 115478, Russia

  • Investigational Site Number : 6202

    Obninsk, 249036, Russia

  • Investigational Site Number : 7201

    Uppsala, 75185, Sweden

  • Investigational Site Number : 901

    Sofia, 1527, Bulgaria

More trials for these conditions

Other studies related to the condition(s) this trial covers.